{"id":"NCT00812981","sponsor":"GlaxoSmithKline","briefTitle":"A Study for Evaluation of GSK Biologicals' Pandemic Influenza Vaccine.","officialTitle":"Non-inferiority Study of GSK Biologicals' Pandemic Influenza Vaccine 1562902A.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-11-15","primaryCompletion":"2009-06-07","completion":"2009-06-07","firstPosted":"2008-12-22","resultsPosted":"2017-06-16","lastUpdate":"2018-08-20"},"enrollment":320,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"PREVENTION"},"conditions":["Influenza"],"interventions":[{"type":"BIOLOGICAL","name":"GSK1562902A","otherNames":[]},{"type":"BIOLOGICAL","name":"GSK1562902A","otherNames":[]}],"arms":[{"label":"1562902A NP GROUP","type":"EXPERIMENTAL"},{"label":"1562902A CP GROUP","type":"EXPERIMENTAL"}],"summary":"This observer-blind study is designed to show the immunological non-inferiority of Thiomersal-free-processed pandemic influenza vaccine as compared to the Thiomersal-containing-processed pandemic influenza vaccine.","primaryOutcome":{"measure":"Titers for Serum H5N1 Haemagglutination-inhibition (HI) Antibodies","timeFrame":"At Day 42","effectByArm":[{"arm":"1562902A NP Group","deltaMin":739.5,"sd":null},{"arm":"1562902A CP Group","deltaMin":621.7,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":7,"exclusionCount":16},"locations":{"siteCount":1,"countries":["Taiwan"]},"refs":{"pmids":["22748624"],"seeAlso":["https://www.clinicalstudydatarequest.com"]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":160},"commonTop":["Pain","Myalgia","Fatigue","Headache","Arthralgia"]}}